We have introduced a variety of amino acid substitutions into carboxyl-terminal CAIA2X sequence (C = cysteine; A = aliphatic; X = any amino acid) of the oncogenic
Ras processing (isoprenylation, proteolysis, and carboxyl methylation), membrane association, and transformation in cultured mammalian cells. While all substitutions were tolerated at the Al position, substitutions at A2 and X reduced transforming activity. The A2 residue was important for both isoprenylation and AAX proteolysis, whereas the X residue dictated the extent and specificity of isoprenoid modification only. Differences were observed between Ras processing in living cells and farnesylation efficiency in a cell-free system. Finally, one farnesylated mutant did not undergo either proteolysis or carboxyl methylation but still displayed efficient membrane association (==50%) and transforming activity, indicating that farnesylation alone can support Ras transforming activity. Since both farnesylation and carboxyl methylation are critical for yeast a-factor biological activity, the three CAAXsignaled modifications may have different contributions to the function of different CAAX-containing proteins.
An association with the plasma membrane is critical for Ras transforming activity (1) (2) (3) , and this association is promoted by a series of three closely linked posttranslational modification steps signaled by the consensus carboxyl-terminal CA1A2X motif (C = cysteine; A = any aliphatic amino acid; X = any amino acid) present in all Ras proteins. Addition of the 15-carbon farnesyl isoprenoid to the cysteine of the CAAX sequence is followed by proteolytic removal of the AAX residues and carboxyl methylation of the now terminal cysteine residue. Mutant Ras proteins lacking either the cysteine or the AAX residues are completely blocked in processing and are cytosolic and completely nontransforming. Posttranslational processing is critical for Ras function, but the precise contribution of each of the three CAAXsignaled processing steps to Ras membrane association and transforming activity remains to be established.
The enzymes responsible for Ras processing are now beginning to be characterized. A cytosolic Ras farnesyltransferase activity, identified in both mammalian (4) (5) (6) and yeast (7, 8) cells, requires recognition of only the CAAX sequence to farnesylate the cysteine residue. In contrast to farnesyltransferase, the enzymatic activities for the AAX proteolysis (9) and carboxyl methylation (9) (10) (11) (12) steps have been detected in the membrane component offractionated cells and tissues.
In vitro studies with both synthetic peptides and chimeric Ras proteins have provided details of the sequence requirements for Ras farnesyltransferase modification. The residue at the A1 position can vary, while a much more restricted set of A2 and X residues permits efficient isoprenoid modification (13) (14) (15) . The X residue also specifies whether the protein is modified by a farnesyl or by a geranylgeranyl group (14, (16) (17) (18) (19) (20) .
While in vitro prenylation studies have been important for defining the sequence requirements for a functional CAAX motif, characterization of all three CAAX-signaled processing steps under physiological conditions with full-length proteins remains to be done. Furthermore, in vivo analyses will be important to establish the relationship between each CAAX-signaled processing step and Ras transforming activity. Therefore, we have used mouse NIH 3T3 cells as an "in vivo" system to address the following questions. (i) Does the Ras farnesyltransferase show in vivo the same specificity for CAAX residues that it does in vitro? (ii) What are the sequence requirements for efficient AAX proteolysis and carboxyl methylation? (iii) What are the relative contributions of the three different CAAX-signaled modifications to Ras membrane association and transforming activity? Our results identify differences between farnesylation efficiency in vitro and Ras processing in vivo, demonstrate a different sequence requirement for farnesylation versus AAX proteolysis, and suggest that farnesyl addition alone is sufficient for Ras membrane association and transforming activity.
MATERIALS AND METHODS
Generation of Ki-Ras4B CAAX Mutant Constructs. For these studies, we chose the Ki-Ras4B protein, which does not undergo the palmitate modification present in the three other human Ras proteins (21, 22) , to avoid any complications due to differences in palmitoylation efficiency that may occur from mutations in the CAAX sequence. Polymerase III (Stratagene) or Taq polymerase chain reaction (PCR) DNA amplification using mutagenic oligonucleotides of an oncogenic [Val12]Ki-Ras4B cDNA sequence was done to generate mutant sequences encoding single amino acid substitutions (see Table 1 ) in the carboxyl-terminal CVIM sequence (residues 185-188). As characterized previously (22) , this Ki-Ras cDNA sequence encodes an additional N-terminal 10 residues from vector-derived sequences, and the resulting chimeric Ki-Ras4B protein migrates at -24 kDa in an SDS/ polyacrylamide gel. This distinct mobility allowed us to clearly distinguish both processing and membrane association of the chimeric Ki-Ras4B proteins from that of the endogenous Ras proteins. All mutated Ki-Ras4B sequences were completely verified by dideoxy sequencing (23) and introduced into the pZIP-NeoSV(x)1 retrovirus vector (24) (25) . Fractionation analysis was done as described (22) . The cytosolic (S100) and membrane-containing (P100) fractions were immunoprecipitated with anti-Ras rat monoclonal antibody Y13-259 (26) (27) (28) (29) . After SDS/PAGE and fluorography, the labeled Ki-Ras4B bands were excised and incubated with 1 M NaOH for 24 hr at 37°C and the ratio of volatile to stable 3H cpm was quantitated.
In Vitro Processing Analysis. In vitro translation and processing were done (9) with a pGEM-3Z (Promega) Ki-Ras4B construct and 17 RNA polymerase. Nuclease-treated reticulocyte lysate (Promega) contains Ras farnesyltransferase activity as well as MVA and farnesyl pyrophosphate for isoprenylation of exogenously added Ras proteins (9) . Translation reactions were supplemented with 5 mM nonradioactive MVA (for complete farnesylation) and with microsomal membranes (Promega) for efficient AAX proteolysis and carboxyl methylation when appropriate. Translations were done in the presence of [35S]methionine/cysteine (1 mCi/ml) and methionine-free amino acid mix (Promega) to detect Ki-Ras4B expression. Translations were done with [3H]MVA (1 mCi/ml) or S-adenosyl-L-methionine (SAM, 1.6 mCi/ml) (82 Ci/mmol; NEN) to detect isoprenylation or carboxyl methylation, respectively. Additionally, when indicated, 50 AM compactin or 2 mM S-adenosyl-L-homocysteine (Sigma) was included to prevent farnesylation (25) or carboxyl methylation (12), respectively.
To characterize the individual modification steps, translation and processing were done in 50-du reaction volumes with the following four conditions: (i) unprocessed-reticulocyte lysate alone in the presence of 50 AM compactin [under these conditions, significant Ras isoprenylation (band 2) will still occur due to the presence of sufficient endogenous amounts of MVA or farnesyl pyrophosphate]; (ii) farnesylation onlyreticulocyte lysate alone supplemented with 5 mM nonradioactive MVA; (iii) farnesylation with proteolytic removal of AAX residues-reticulocyte lysate with MVA and microsomal membranes with S-adenosylhomocysteine; and (iv) full processing-reticulocyte lysate with MVA and microsomal membranes. After translation and radiolabeling, 10 specific processing steps were critical for Ki-Ras4B membrane association and transforming activity. Our initial analyses of the expression of Ki-Ras4B CAAX mutant proteins in NIH 3T3 cells identified a variety of electrophoretic profiles on SDS/PAGE, with each CAAX mutant expressing various amounts of three species of distinct electrophoretic mobility. To determine whether these three species corresponded to differentially processed forms of Ki-Ras4B, we analyzed the posttranslational modifications corresponding to each electrophoretic species by using an in vitro reticulocyte lysate system supplemented with microsomal membranes (9) . Using the four conditions described in Materials and Methods, we were able to isolate each posttranslational processing step in vitro (Fig. 1) . The three electrophoretic species of Ki-Ras4B are the unprocessed protein (band 1); the partially processed forms, which are farnesylated only, or farnesylated and proteolyzed (band 2); and the completely processed, farnesylated, proteolyzed, and carboxylmethylated protein (band 3). Thus, the modifications of farnesylation and carboxyl methylation, but not proteolysis, account for the altered electrophoretic mobility of the fully processed Ki-Ras4B. The three species detected in vitro corresponded to the three electrophoretic species expressed in NIH 3T3 cells (data not shown). Although band 2 can represent either the farnesylated or the farnesylated and proteolyzed form of Ki-Ras4B in vitro, since proteolytic removal of the AAX residues of all mutants generates the same carboxyl-terminal farnesylcysteine substrate for carboxyl methylation in vivo, the band 2 species detected in vivo is believed to represent only the farnesylated form.
Differential Amino Acid Tolerance of the Al, A2, and X Positions for Processing in Vivo. To compare the ability of the A1, A2, and X residues to signal processing, the same amino acid substitutions were introduced into each position and processing was characterized in transfected NIH 3T3 cells. Like the wild-type protein, mutant proteins with cysteine substitutions at each position underwent complete processing, with no band 1 or 2 detected (Table 1) into crude soluble (S) and particulate (P) fractions. Labeled proteins were immunoprecipitated from each fraction with the Y13-259 antiRas monoclonal antibody, resolved by SDS/PAGE, and detected by fluorography. Arrows designate the three electrophoretic forms of Ki-Ras4B as described in Fig. 1 . Additional bands detected in the 21-kDa region represent either Ki-Ras4B protein expressed from the authentic ATG start site of Ki-Ras4B in the chimeric constructs (*) or endogenous Ras proteins (.).
consequences for the three AAX positions. While neither substitution perturbed processing when made at the A1 position (186D and 186Y) (Fig. 2, lanes c, d, i , and j), both impaired processing significantly when made at A2 (187D and 187Y) (lanes e, f, k, and 1). The 187D protein expressed in vivo was localized exclusively in the cytosol, and its mobility corresponded solely to that of the unprocessed protein (band 1) (lanes e and f). In contrast, the same substitution at X (188D) resulted in two electrophoretic species (lanes g and h) . The major species was the unprocessed, cytosolic protein (band 1), while the second species corresponded to the fully processed, membrane-associated protein (band 3). A tyrosine substitution resulted in a partially processed protein when made at the A2 position (band 2), but a fully processed protein (band 3) when introduced at X (lanes i-n). Both aspartic acid (187D) and lysine (187K) substitutions at A2, as well as lysine (188K) and arginine (188R) substitutions at X, completely abolished processing (band 1), whereas the 188E protein was only partially processed (bands 1 and 3; data not shown). These data demonstrate that the amino acid requirements for a functional CAAX motif are not stringent for the A1 residue, are most stringent for the A2 residue, and are also restrictive for the X position.
The A2 Residue Influences Both Farnesylation and Proteolysis, Whereas the X Residue Influences the Rate and Specificity ofIsoprenylation Only. While certain amino acid substitutions at both the A2 and X positions prevented complete posttranslational processing, the nature ofthe defect in processing was distinctly different at each position. For example, the mutant protein with a glycine at A2 (187G) was expressed predominantly as unprocessed protein (band 1), with a minor amount of farnesylated protein (band 2); no fully processed protein was detected (Fig. 3A, lanes c and d) . Similarly, the A2 tyrosine mutant (187Y) was efficiently farnesylated (band 2) but was not further processed to the mature form (band 3) (lanes e and f). The band 2 forms of both 187G and 187Y proteins were radiolabeled with [3H]MVA, and -50% of the farnesylated species was present in the membrane fraction (Fig. 3B, lanes c-f) . Further particulate (P) fractions, and resolved by SDS/PAGE. Labeled proteins were detected by fluorography. Arrows designate the three electrophoretic forms of Ki-Ras4B as described in Fig. 1 . The internally initiated (*) or endogenous (-) Ras proteins are designated as described in Fig. 2 .
In contrast to the partially processed band 2 profiles of the A2 mutant proteins, partially processed X-position mutants (188D and 188E) displayed different profiles consisting oftwo forms (Fig. 3A, lanes g-j) , one of which corresponded to the unprocessed, cytosolic protein (band 1), but the other of which corresponded to the fully processed, membraneassociated protein (band 3). Thus, these substitutions perturbed only the rate or degree of farnesylation, but the farnesylated form was then completely processed to the mature form. Finally, pulse-chase analysis (data not shown) showed that some X substitutions (e.g., 188G and 188Y) perturbed the rate but not the steady-state degree of processing (Table 1) . Therefore, the sequence requirements for farnesylation and proteolysis are clearly different, with the X residue influencing primarily the farnesylation step whereas the A2 residue is important for both efficient farnesylation and AAX proteolysis.
Under the metabolic labeling conditions used in these studies, while proteins expected to be modified by a farnesyl isoprenoid were labeled efficiently by [3H]MVA, proteins expected to be modified by a geranylgeranyl group were very poorly labeled (20, 29) . The poor labeling of geranylgeranylmodified proteins is believed to reflect not the degree of isoprenoid modification but rather the significantly lower specific activity of the geranylgeranyl pyrophosphate versus farnesyl pyrophosphate pools generated in vivo during our 16-18 hr labeling. A comparison of the degree of radiolabeling of the farnesylated wild-type Ki-Ras4B protein and the geranylgeranyl-modified 188L protein provides a striking example of this differential radiolabeling. Metabolic labeling with [35S]methionine/cysteine indicated that the two proteins were expressed at comparable levels and were converted predominantly to the fully processed form (Fig. 4, lanes a-d) . However, parallel cultures labeled with [H]MVA showed incorporation into the wild-type protein that was readily detectable after a 3-day autoradiographic exposure, whereas no [3H]MVA incorporation was detected in the 188L mutant (lanes g and h) . While the endogenous Ras proteins were efficiently labeled with [3H]MVA, a faint band of the 188L Ki-Ras4B mutant was detected only after an 11-week autoradiographic exposure (compare lanes j and k). We have observed that, like leucine, the substitution of glycine (lanes i and 1), threonine, phenylalanine, tyrosine, and asparagine (data not shown) at the X position also resulted in fully processed, membrane-associated proteins that displayed ited efficient metabolic labeling with [3HJMVA (data not shown). Thus, it is likely that proteins with the latter substitutions retain modification by farnesylation, while proteins with the former substitutions are altered in their isoprenoid specificity and are modified instead by a geranylgeranyl isoprenoid.
DISCUSSION
Our data on the processing in vivo of 22 Ki-Ras4B CAAX mutants are generally consistent with farnesylation results in vitro but also identify several important differences. As in vitro, we observed that the A1 position was more tolerant than the A2 position for a variety of amino acid substitutions. Basic and aromatic residues were tolerated at A1 but not at A2. Substitutions at A1 and A2 were found to influence prenylation efficiency but not specificity. Substitutions at X influenced the efficiency and specificity (farnesylation versus geranylgeranylation) of isoprenoid addition. Overall, our observations in vivo, together with results from studies in vitro, suggest that the A1 and A2 positions do not require aliphatic amino acids. Therefore, the CAAX motif should more appropriately be referred to as a CXXX motif.
One significant difference between farnesylation efficiency in vitro and isoprenylation and transforming activity in vivo was observed with aromatic substitutions at the A2 position. A recent study (15) determined that CAAX tetrapeptide sequences with aromatic amino acids at the A2 position were potent inhibitors of, but not substrates for, Ras farnesyltransferase activity in vitro. Such peptides represent good candidates for inhibitors of Ras farnesyltransferase because they would not be modified and inactivated by farnesylation. However, we found that a Ki-Ras4B CAAX mutant protein terminating in CVYM (187Y) did undergo efficient isoprenylation (>95%) when expressed in NIH 3T3 cells. These results suggest the possibility that an additional Ras farnesyltransferase(s) other than the presently identified activity may exist. Alternatively, they may reflect the possibility that the activities of Ras farnesyltransferase may not be identical in vitro and in vivo or may differ with tetrapeptides versus intact full-length proteins.
We observed that all mutant Ki-Ras4B proteins with X residues that should allow efficient farnesyl modification as predicted in vivo (i.e., where X = S, C, Q, or M) exhibited potent transforming activities. However, the effect on transforming activity of a few X-position substitutions did not reflect farnesylation efficiency in vitro. For example, CAAX peptides terminating in either leucine or phenylalanine were neither effective inhibitors of nor substrates for Ras farnesylation in vitro (13) (14) (15) 17) but, instead, were efficiently geranylgeranylated (14, 16, (18) (19) (20) . We observed that KiRas4B mutant proteins in which X = L or F retained full transforming activity (0.82-0.96 relative focus-forming activity). One explanation for the apparent discrepancy between the in vitro farnesylation results and the transforming activity of these mutants is that, although they are not farnesylated, they are geranylgeranylated in vivo, and Ras transforming activity can be facilitated by either isoprenoid. Consistent with this possibility, Ras transforming activity can be promoted equally by either farnesylation or geranylgeranylation (20, 30) . Thus, CAAX sequences with X-position residues that are able to signal efficient isoprenoid modification, independent of whether a farnesyl or geranylgeranyl moiety is added, would be expected to exhibit strong transforming activity.
Substitution of tyrosine at A2 (187Y) resulted in a significant impairment of the AAX proteolysis and carboxyl methylation steps, without abolishing farnesylation. The efficient membrane association (=50%o) and transforming activity (0.55 relative focus-forming activity) of the 187Y mutant protein suggests that isoprenoid modification alone is sufficient for oncogenic Ras function. These results are consistent with the observation that carboxyl methylation, although important, is not essential for the membrane association or function ofyeast RAS2 (31) . Thus, pharmacologic inhibitors of farnesylation, but not of proteolysis or carboxyl methylation, are likely to be effective for blocking oncogenic Ras function in tumors. These results contrast with the observations that both farnesylation and carboxyl methylation are critical for the biological activity of yeast a-type mating factor (32) (33) (34) . Thus, the importance of isoprenylation, proteolysis, and carboxyl methylation for protein function is likely to be different for each protein that undergoes CAAX-signaled modifications.
While both the A2 and X positions showed similar intolerance to amino acid substitutions with respect to effect on transforming activity, the consequences of A2 and X residue substitutions for processing were distinctly different. Substitutions at X perturbed isoprenylation but not AAX proteolysis. In contrast, substitutions at A2 perturbed both isoprenylation and AAX proteolysis. Thus, the sequence requirements to signal these two modifications are clearly different.
Recent studies in vitro have begun to establish the sequence requirements for a functional CAAX motif for isoprenoid modification. The in vivo studies described here provide further characterization of the sequence requirements for the CAAX motif to signal isoprenylation and AAX proteolysis. The differences that we have observed between Ras processing in living cells and farnesylation in a cell-free system demonstrate the importance of evaluating the activity of prenyltransferases under physiological conditions. The generation of partially processed Ras proteins has allowed us to begin to distinguish the role of each modification in facilitating Ras membrane association and transforming activity. Further studies will be required to determine the precise contribution of each CAAX-signaled processing step to the biological function of Ras proteins and to determine whether these contributions are the same for isoprenylated proteins such as additional members of the Ras superfamily, the nuclear lamins, and the y subunits of heterotrimeric guanine nucleotide-binding proteins (3) .
